List view / Grid view
27 May 2016 | By Victoria White, Digital Content Producer
The CHMP has adopted a positive opinion of Shire’s Revestive (teduglutide) solution for injection in paediatric patients with short bowel syndrome...
29 March 2016 | By Victoria White
The US District Court for Southern Florida has upheld Shire's patent for Lialda (mesalamine) delayed release tablets for adults with ulcerative colitis...
25 January 2016 | By Victoria White
Shire resubmitted the NDA in response to the complete response letter (CRL) the company received from the FDA in October last year...
20 January 2016 | By Black Swan Analysis
Speciality pharma firm Shire has agreed to buy Baxalta for around $32 billion (£22 billion), to further expand its portfolio of treatments for rare diseases...
11 January 2016 | By Victoria White
The combination of Shire and Baxalta will create the number one rare diseases platform in revenue and pipeline depth...
3 November 2015 | By Victoria White
Shire has announced that it is to acquire Dyax, a company focused on the development of plasma kallikrein inhibitors for the treatment of hereditary angioedema, for approximately $5.9 billion...
27 October 2015 | By Victoria White
A Phase 3 trial of lifitegrast met its primary endpoint of significantly improving patient-reported symptoms of dry eye disease from baseline to day 84...
20 October 2015 | By Victoria White
In the run up to ADHD Awareness Week, European Pharmaceutical Review spoke with Tom Croce, Head of Global Patient Advocacy at Shire, to find out more about the awards and what makes Shire a 'patient-centric' company...
13 October 2015 | By Victoria White
Cinryze is being studied as an adjunct treatment to Donor Specific Antibodies (DSA) reduction therapy in kidney transplant patients with acute antibody mediated rejection...
21 September 2015 | By Victoria White
The EC has granted Marketing Authorisation for Intuniv for the treatment of ADHD in children and adolescents for whom stimulants are not suitable...
4 August 2015 | By Victoria White
Shire made a proposal to Baxalta on 10 July 2015 to combine the companies in an all-stock transaction worth approximately $30.6 billion...
3 August 2015 | By Victoria White
Shire has acquired Foresight Biotherapeutics, gaining global rights to FST-100 - a therapy in development for the treatment of infectious conjunctivitis...
24 July 2015 | By Victoria White
The CHMP has adopted a positive opinion recommending the approval of Shire’s Intuniv for the treatment of ADHD in children and adolescents...
3 June 2015 | By
The EMA has approved Resolor for use in adults for the symptomatic treatment of chronic constipation in whom laxatives fail to provide adequate relief...
13 April 2015 | By Victoria White
Shire has announced that the FDA has accepted for filing the New Drug Application (NDA) for Lifitegrast and granted a Priority Review designation...
